Borr Drilling BORR
Three insiders bought $49.7M over 30 days, within the 30-day window
Last open-market buy
- Tor Olav Troim $48M
- Harvey Edward Snowling $1.5M
- De Oliveira Bruno Morand $200K
Form 4
Insider buys and sales
Source: Form 4 filings on SEC EDGAR
Type a ticker for one company's Form 4s, or read today's open-market trades at companies with a public float under $300M (All companies is one tap away): buys first, then sales, cluster buys and each insider's record across companies.
Open-market buys, last day0
Cluster buys, last 30 days, all companies19
Open-market sales, last day14
Planned sales (10b5-1), last day6
Insiders you follow
Cluster buys, last 30 days, all companies
6 of 19 companies whose last cluster buy was in the last 30 days, those with a public float under $2B first.
Pampa Energy PAM
Three insiders bought $42.7M over 21 days, within the 30-day window
Last open-market buy
- Marcos Marcelo Mindlin $35.1M
- Damian Miguel Mindlin $5.6M
- Gustavo Mariani $2M
Northpointe Bancshares NPB
Four insiders bought $1.8M over 6 days, within the 30-day window
Last open-market buy
- Charles Alan Williams $1.5M
- Carrie L Boer $185K
- Joseph B Long $50K
- Rajeev Kumar Chaudhary $47K
Rapport Therapeutics RAPP
Six insiders bought $1.7M over 3 days, within the 30-day window
Last open-market buy
- Steven M Paul $974K
- John Maraganore $249K
- Troy A. Ignelzi $144K
- Wendy B. Young $100K
- Paul M Silva $100K
- Ramiro Sanchez $98K
Upbound Group UPBD
Six insiders bought $1.3M over 8 days, within the 30-day window
Last open-market buy
- Jeffrey J Brown $447K
- Glenn P Marino $393K
- Halim Khouri $251K
- Rebecca Wooters $99K
- Balaji Kumar $50K
- Molly Langenstein $50K
Stewart Information Services STC
Five insiders bought $461K over 4 days, within the 30-day window
Last open-market buy
- Frederick H Eppinger $133K
- Thomas G Apel $95K
- C Allen Bradley Jr $95K
- William S. Corey Jr. $94K
- Deborah Jane Matz $44K
Trades filed since Nov 4
Notes on each row are as each Form 4 states them, next to SEC Tracker's own records of the company's filings and other insiders' buys. The Stake column is the change in their holding.
| Traded | Company | Insider | Trade | Value | Stake | Notes |
|---|---|---|---|---|---|---|
| Nov 2, 2026 Filed Nov 4, 2026 | Regeneron Pharmaceuticals REGN | Joseph J Larosa Officer | Tax withholding 8,686 shares | $8.3M at $950.50 | The same day as a Form 144 notice of a planned insider sale filed Nov 2, 2026. | |
| Nov 2, 2026 Filed Nov 4, 2026 | Regeneron Pharmaceuticals REGN | George L Sing Director | Open-market sale 7,073 shares | $6.8M at $965.38 | −20% | The filing does not mark this sale as under a Rule 10b5-1 plan. The same day as a Form 144 notice of a planned insider sale filed Nov 2, 2026. |
| Nov 3, 2026 Filed Nov 5, 2026 | Regeneron Pharmaceuticals REGN | Huda Y Zoghbi Director | Open-market sale 6,939 shares | $6.7M at $970.42 | −76% | The filing does not mark this sale as under a Rule 10b5-1 plan. The same day as a Form 144 notice of a planned insider sale filed Nov 3, 2026. |
| Nov 2, 2026 Filed Nov 4, 2026 | Regeneron Pharmaceuticals REGN | Joseph J Larosa Officer | Option exercise 12,283 shares | $4.7M at $381.92 | The same day as a Form 144 notice of a planned insider sale filed Nov 2, 2026. | |
| Nov 2, 2026 Filed Nov 4, 2026 | Regeneron Pharmaceuticals REGN | George L Sing Director | Open-market sale 4,338 shares | $4.2M at $963.47 | −10% | The filing does not mark this sale as under a Rule 10b5-1 plan. The same day as a Form 144 notice of a planned insider sale filed Nov 2, 2026. |
| Nov 2, 2026 Filed Nov 4, 2026 | Regeneron Pharmaceuticals REGN | Christopher R. Fenimore EVP Finance CFO | Tax withholding 4,243 shares | $4M at $950.50 | The same day as a Form 144 notice of a planned insider sale filed Nov 2, 2026. | |
| Nov 2, 2026 Filed Nov 4, 2026 | Regeneron Pharmaceuticals REGN | Joseph J Larosa Officer | Open-market sale 3,939 shares | $3.8M at $965.41 | −9% | The filing does not mark this sale as under a Rule 10b5-1 plan. The same day as a Form 144 notice of a planned insider sale filed Nov 2, 2026. |
| Nov 2, 2026 Filed Nov 4, 2026 | Regeneron Pharmaceuticals REGN | Christine A Poon Director | Open-market sale 3,203 shares | $3.1M at $969.50 | −34% | The filing does not mark this sale as under a Rule 10b5-1 plan. The same day as a Form 144 notice of a planned insider sale filed Nov 2, 2026. |
| Nov 2, 2026 Filed Nov 4, 2026 | Regeneron Pharmaceuticals REGN | Christine A Poon Director | Option exercise 7,830 shares | $2.9M at $376.69 | The same day as a Form 144 notice of a planned insider sale filed Nov 2, 2026. | |
| Nov 2, 2026 Filed Nov 4, 2026 | Regeneron Pharmaceuticals REGN | George L Sing Director | Option exercise 7,830 shares | $2.9M at $376.69 | The same day as a Form 144 notice of a planned insider sale filed Nov 2, 2026. | |
| Nov 3, 2026 Filed Nov 5, 2026 | Regeneron Pharmaceuticals REGN | Huda Y Zoghbi Director | Option exercise 7,439 shares | $2.8M at $380.95 | The same day as a Form 144 notice of a planned insider sale filed Nov 3, 2026. | |
| Nov 2, 2026 Filed Nov 4, 2026 | Regeneron Pharmaceuticals REGN | George L Sing Director | Option exercise 7,439 shares | $2.8M at $380.95 | The same day as a Form 144 notice of a planned insider sale filed Nov 2, 2026. | |
| Nov 2, 2026 Filed Nov 4, 2026 | Regeneron Pharmaceuticals REGN | George L Sing Director | Open-market sale 2,670 shares | $2.6M at $964.57 | −7% | The filing does not mark this sale as under a Rule 10b5-1 plan. The same day as a Form 144 notice of a planned insider sale filed Nov 2, 2026. |
| Nov 2, 2026 Filed Nov 4, 2026 | Regeneron Pharmaceuticals REGN | George L Sing Director | Open-market sale 2,522 shares | $2.4M at $962.61 | −6% | The filing does not mark this sale as under a Rule 10b5-1 plan. The same day as a Form 144 notice of a planned insider sale filed Nov 2, 2026. |
| Nov 2, 2026 Filed Nov 4, 2026 | Regeneron Pharmaceuticals REGN | Christine A Poon Director | Open-market sale 2,499 shares | $2.4M at $968.58 | −21% | The filing does not mark this sale as under a Rule 10b5-1 plan. The same day as a Form 144 notice of a planned insider sale filed Nov 2, 2026. |
| Nov 2, 2026 Filed Nov 4, 2026 | Regeneron Pharmaceuticals REGN | Christopher R. Fenimore EVP Finance CFO | Option exercise 6,000 shares | $2.3M at $381.92 | The same day as a Form 144 notice of a planned insider sale filed Nov 2, 2026. | |
| Nov 4, 2026 | Mirum Pharmaceuticals MIRM | Christopher Peetz CEO | Planned sale (10b5-1) 20,000 shares | $1.8M at $90.00 | −9% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. The same day as a Form 144 notice of a planned insider sale filed Nov 4, 2026. |
| Nov 2, 2026 Filed Nov 4, 2026 | Regeneron Pharmaceuticals REGN | George L Sing Director | Open-market sale 1,522 shares | $1.5M at $966.27 | −5% | The filing does not mark this sale as under a Rule 10b5-1 plan. The same day as a Form 144 notice of a planned insider sale filed Nov 2, 2026. |
| Nov 4, 2026 | Arcutis Biotherapeutics ARQT | Masaru Matsuda EVP, Chief Legal Officer | Planned sale (10b5-1) 40,000 shares | $1.4M at $34.32 | −26% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. The same day as the company's 8-K filed Nov 4, 2026. |
| Nov 3, 2026 Filed Nov 4, 2026 | United Therapeutics UTHR | Martine A Rothblatt Chairperson & CEO | Planned sale (10b5-1) 2,202 shares | $1.3M at $600.73 | −1% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. 1 day after a Form 144 notice of a planned insider sale filed Nov 2, 2026. |
Insider records
The 10 insiders in these trades with the most bought and sold on the open market across every company, in SEC Tracker's records.
| Insider | Buys | Sales | Bought | Sold | Companies |
|---|---|---|---|---|---|
| Bruce C Cozadd | 1 | 182 | $86K | $98.6M | 2 |
| Martine A Rothblatt | 0 | 176 | $82M | 1 | |
| Sean Maduck | 0 | 75 | $62.9M | 1 | |
| Christopher R. Fenimore | 0 | 84 | $30.3M | 1 | |
| Christopher Peetz | 7 | 34 | $314K | $27.6M | 2 |
| Christine A Poon | 0 | 17 | $22.2M | 1 | |
| George L Sing | 0 | 9 | $20.4M | 1 | |
| Huda Y Zoghbi | 0 | 36 | $19.1M | 1 | |
| Masaru Matsuda | 2 | 38 | $19K | $4.9M | 1 |
| Joseph J Larosa | 0 | 2 | $4.3M | 1 |
Open-market trades are Form 4 transaction codes P (purchase) and S (sale). Planned sales are those the filing marks as made under a Rule 10b5-1 plan. A P-code buy at the offering price within a day of the company's FWP, 424B prospectus or offering 8-K is marked Bought in the offering and left out of open-market buy counts and cluster buys. Prices and values are as stated in each Form 4. Stock prices aren't shown on this page. Not investment advice.